Profile of darunavir in the management of treatment-experienced HIV patients

Darunavir (formerly TMC114) is a second-generation, sulfonamide-based, peptidomimetic protease inhibitor (PI) with a modified 3-dimensional structure enabling more efficient binding to HIV protease. It has become an important drug, in combination with low-dose ritonavir boosting, in the treatment of...

Descripción completa

Detalles Bibliográficos
Autores principales: Wolfe, Cameron, Hicks, Charles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2009
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3218680/
https://www.ncbi.nlm.nih.gov/pubmed/22096376
_version_ 1782216706340421632
author Wolfe, Cameron
Hicks, Charles
author_facet Wolfe, Cameron
Hicks, Charles
author_sort Wolfe, Cameron
collection PubMed
description Darunavir (formerly TMC114) is a second-generation, sulfonamide-based, peptidomimetic protease inhibitor (PI) with a modified 3-dimensional structure enabling more efficient binding to HIV protease. It has become an important drug, in combination with low-dose ritonavir boosting, in the treatment of both antiretroviral-naïve and multiclass-experienced patients. Growing data now exist suggesting it possesses a high barrier to resistance and requires multiple PI mutations in order to suffer reduced virological potency.
format Online
Article
Text
id pubmed-3218680
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-32186802011-11-17 Profile of darunavir in the management of treatment-experienced HIV patients Wolfe, Cameron Hicks, Charles HIV AIDS (Auckl) Review Darunavir (formerly TMC114) is a second-generation, sulfonamide-based, peptidomimetic protease inhibitor (PI) with a modified 3-dimensional structure enabling more efficient binding to HIV protease. It has become an important drug, in combination with low-dose ritonavir boosting, in the treatment of both antiretroviral-naïve and multiclass-experienced patients. Growing data now exist suggesting it possesses a high barrier to resistance and requires multiple PI mutations in order to suffer reduced virological potency. Dove Medical Press 2009-09-29 /pmc/articles/PMC3218680/ /pubmed/22096376 Text en © 2009 Wolfe and Hicks, publisher and licensee Dove Medical Press Ltd This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Wolfe, Cameron
Hicks, Charles
Profile of darunavir in the management of treatment-experienced HIV patients
title Profile of darunavir in the management of treatment-experienced HIV patients
title_full Profile of darunavir in the management of treatment-experienced HIV patients
title_fullStr Profile of darunavir in the management of treatment-experienced HIV patients
title_full_unstemmed Profile of darunavir in the management of treatment-experienced HIV patients
title_short Profile of darunavir in the management of treatment-experienced HIV patients
title_sort profile of darunavir in the management of treatment-experienced hiv patients
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3218680/
https://www.ncbi.nlm.nih.gov/pubmed/22096376
work_keys_str_mv AT wolfecameron profileofdarunavirinthemanagementoftreatmentexperiencedhivpatients
AT hickscharles profileofdarunavirinthemanagementoftreatmentexperiencedhivpatients

Ejemplares similares